|
09 Jan 2020 |
Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40
|
|
09 Jan 2020 |
AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise
|
|
09 Jan 2020 |
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
|
|
09 Jan 2020 |
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
|
|
09 Jan 2020 |
Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201
|
|
09 Jan 2020 |
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
|
|
09 Jan 2020 |
Agenus Commences Phase 1 trial with AGEN1223
|
|
09 Jan 2020 |
Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector
|
|
09 Jan 2020 |
Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapy
|
|
09 Jan 2020 |
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
|
|
09 Jan 2020 |
OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
|
|
09 Jan 2020 |
Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
|
|
09 Jan 2020 |
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
|
|
09 Jan 2020 |
Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
|
|
09 Jan 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy
|
|
08 Jan 2020 |
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
|
|
08 Jan 2020 |
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
|
|
08 Jan 2020 |
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
|
|
08 Jan 2020 |
Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
|
|
08 Jan 2020 |
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
|
